Table 1

Characteristics of the Patients

CharacteristicsHealthy Controls (n = 15)SA Patients (n = 15)UA Patients (n = 15)
Age, yrs66.3 ± 3.465.5 ± 3.468.0 ± 2.2
Gender, n
 Male91210
 Female635
Risk factors, n (%)
 Family history3 (20.0)5 (33.3)5 (33.3)
 Hypertension5 (33.3)13 (86.7)14 (93.3)
 Current smoking4 (26.7)3 (20.0)1 (6.7)
 Hypercholesterolemia2 (13.3)15 (100.0)14 (93.3)
 Diabetes05 (33.3)5 (33.3)
Therapy (at the time of hospital presentation), n (%)
 Anti-platelet
  ASA013 (86.7)15 (100.0)
  Ticlopidine02 (13.3)1 (6.7)
  Clopidogrel01 (6.7)1 (6.7)
 Beta-blockers2 (13.3)10 (66.7)12 (80.0)
 ACE inhibitors/ARBs5 (33.3)6 (40.0)8 (53.3)
 Nitrates08 (53.3)10 (66.7)
 Statins08 (53.3)10 (66.7)
 Calcium-channel blockers05 (33.3)4 (26.7)
Angiographic findings
 1-vessel diseasen.d.1 (6.7)1 (6.7)
 2-vessel diseasen.d.5 (33.3)4 (26.7)
 3-vessel diseasen.d.9 (60.0)10 (66.7)
Platelets (109/l)200.8 ± 11.9202.1 ± 13.2205.5 ± 14.1
MPV (fl)10.8 ± 0.210.9 ± 0.411.7 ± 0.4
WBC (106/l)6,605.4 ± 706.06,808.0 ± 688.46,397.1 ± 254.4
Monocytes (106/l)400.1 ± 35.8358.0 ± 52.4426.0 ± 67.8

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; MPV = mean platelet volume; n.d. = not determined; SA = stable angina; UA = unstable angina; WBC = white blood cells.

  • Plus-minus values are mean ± SE.

  • p < 0.05 for the comparison with the other 2 groups.